Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications.
McElvaney OF, Asakura T, Meinig SL, Torres-Castillo JL, Hagan RS, Gabillard-Lefort C, Murphy MP, Thorne LB, Borczuk A, Reeves EP, Zumwalt RE, Mikami Y, Carroll TP, Okuda K, Hogan G, McElvaney OJ, Clarke J, McEvoy NL, Mallon PW, McCarthy C, Curley G, Wolfgang MC, Boucher RC, McElvaney NG.
McElvaney OF, et al.
EBioMedicine. 2022 Mar;77:103894. doi: 10.1016/j.ebiom.2022.103894. Epub 2022 Feb 22.
EBioMedicine. 2022.
PMID: 35217407
Free PMC article.
The airway anti-protease, secretory leukoprotease inhibitor was decreased in SARS-CoV-2-infected lungs and cleaved in TA. In nsARDS, plasma AAT levels were elevated but TA samples had less AAT cleavage, with no detectable active NE in most samples. ...
The airway anti-protease, secretory leukoprotease inhibitor was decreased in SARS-CoV-2-infected lungs and cleaved in TA. In nsARDS, …